Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
AstraZeneca
Express Scripts
Johnson and Johnson
Mallinckrodt

Last Updated: December 3, 2022

Enasidenib mesylate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic sources for enasidenib mesylate and what is the scope of patent protection?

Enasidenib mesylate is the generic ingredient in one branded drug marketed by Celgene Corp and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Enasidenib mesylate has one hundred and eight patent family members in thirty-nine countries.

One supplier is listed for this compound.

Summary for enasidenib mesylate
Recent Clinical Trials for enasidenib mesylate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Children's Oncology GroupPhase 2
City of Hope Medical CenterPhase 1
National Cancer Institute (NCI)Phase 1

See all enasidenib mesylate clinical trials

Pharmacology for enasidenib mesylate

US Patents and Regulatory Information for enasidenib mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Celgene Corp IDHIFA enasidenib mesylate TABLET;ORAL 209606-001 Aug 1, 2017 RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Celgene Corp IDHIFA enasidenib mesylate TABLET;ORAL 209606-002 Aug 1, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Celgene Corp IDHIFA enasidenib mesylate TABLET;ORAL 209606-002 Aug 1, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Celgene Corp IDHIFA enasidenib mesylate TABLET;ORAL 209606-001 Aug 1, 2017 RX Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Celgene Corp IDHIFA enasidenib mesylate TABLET;ORAL 209606-001 Aug 1, 2017 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Celgene Corp IDHIFA enasidenib mesylate TABLET;ORAL 209606-002 Aug 1, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Celgene Corp IDHIFA enasidenib mesylate TABLET;ORAL 209606-002 Aug 1, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for enasidenib mesylate

Country Patent Number Title Estimated Expiration
China 104114543 Therapeutically active compounds and their methods of use See Plans and Pricing
Japan 6742905 See Plans and Pricing
European Patent Office 3984997 COMPOSÉS THÉRAPEUTIQUEMENT ACTIFS ET LEURS PROCÉDÉS D'UTILISATION (THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE) See Plans and Pricing
South Africa 201405163 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE See Plans and Pricing
Japan 2015503571 治療活性化合物およびその使用方法 See Plans and Pricing
Mexico 2016001361 COMPUESTOS TERAPEUTICAMENTE ACTIVOS Y SUS METODOS DE USO. (THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE.) See Plans and Pricing
Poland 2800743 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Mallinckrodt
McKesson
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.